Abstract
Objective Nitric oxide synthase is the key enzyme of the conversion of L-arginine to L-citrulline and nitric oxide. We conducted a study to investigate the association between positive inducible nitric oxide synthase (iNOS) mRNA expression and recurrence of bladder cancer. Materials and Methods Seventy-one patients with primary non-muscleinvasive bladder cancer were enrolled in this study. Tumor tissues were harvested during transurethral resection of bladder tumors. All operations were performed at the same hospital. Recurrence-free patients were followed up for at least 1 year unless tumors recurred during that time. The median intervals of follow-up were 34 months in the recurrence-free group and 12 months in the recurrence group. iNOS mRNA was detected using the RT-PCR-based method. Results Bladder cancer patients with positive iNOS mRNA expression had a higher recurrence risk (18.7% vs. 2.6%; p = 0.04). After adjusting for other risk factors, a statistical significance remained ( p = 0.04; hazards ratio = 13.27; 95% CI = 1.07–164.36). The patients also had reduced recurrence-free survival ( p = 0.019). Conclusion The positive expression of iNOS mRNA may be a useful prognostic indicator of bladder cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
